Novo Nordisk Just Delivered Great News For Investors. Is …
▲ S&P 500 +—%|▲ Stock Advisor +—%Join The Motley Fool
S&P 500
7,376.86
+0.3%
+23.13
DJI
51,285.73
-0.5%
-237.33
NASDAQ
24,579.42
+1.1%
+264.43
Bitcoin
$75,660.00
-0.3%
-$198.53
SPCX
$134.27
+8.6%
+$10.65
AAPL
$342.37
-0.5%
-$1.80
AMZN
$259.30
-0.3%
-$0.91
GOOG
$283.93
+0.8%
+$2.19
META
$610.15
+0.8%
+$5.07
MSFT
$530.61
-1.0%
-$5.32
NVDA
$186.64
+2.8%
+$5.04
TSLA
$358.22
+4.2%
+$14.53
Free ArticleExplore Premium Services
By Prosper Junior Bakiny – Nov 7, 2026 at 6:20PM EST
Key Points
-
Novo’s third-quarter update was strong, largely due to its oral weight-loss pill.
-
The company has several catalysts ahead that could help power strong results over the medium term.
Novo’s weight loss pill continues to perform well
At first glance, Novo’s third-quarter results didn’t seem particularly impressive, as some of the company’s longtime growth drivers underperformed. For instance, sales of Ozempic, the company’s famous diabetes medicine, were 29.7 billion Danish kroner (about $4.5 billion), down 3% compared to the year-ago period. The company’s weight-loss medicine, Wegovy, recorded sales of 20.4 billion DKK (about $3.1 billion), roughly flat compared with the prior-year quarter.
However, several other medicines helped pick up the slack, and arguably none was more important than Novo’s oral Wegovy. The company launched this weight loss pill — the first of its kind to earn approval — in January. The Wegovy pill has helped attract many patients who were hesitant to start treatment with injectables. Novo reported that, as of June, oral Wegovy had surpassed three million prescriptions, and more than 80% were for patients who had never taken GLP-1s before. In the third quarter, oral Wegovy generated 5.4 billion DKK (about $810 million) in revenue.
Novo’s total net sales were 79.2 billion DKK (about $11.9 billion), up 6% year over year. The company’s net income dropped by 16% year over year to 16.7 billion DKK (about $2.5 billion), largely due to non-cash impairment charges. Still, Novo’s results beat analyst estimates, and the pharmaceutical company also raised its guidance for the fiscal year 2026.
It now expects revenue to be flat (at the midpoint) year over year, while the previous guidance implied a 3% year-over-year drop at the midpoint. It’s no wonder Novo’s s jumped ing this beat-and-raise quarter. But what’s next for the drugmaker?
NVO – Novo Nordisk
$40.31+$0.01 (+0.03%)
NYSE · As of 4:00 PM ET 11/06/26
Premium Feature
Key data points
Market capMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.$134.87B
Day’s range$39.53 – $40.55
52wk range$35.12 – $64.16
Volume9.2M
Avg volume12.2M
Gross margin82.02%
Dividend yield4.46%
More growth ahead
There are several catalysts ahead that could help Novo improve its financial performance. Let’s consider three of them. First, the company could make meaningful progress with oral Wegovy. The medicine has now been approved in several other countries, including Germany and the U.K.
These markets might not be as lucrative as the U.S., but they should move the needle for the company. Novo will also ly attract brand-new GLP-1 patients in these regions. The company is also looking to earn label expansions for oral Wegovy. Novo has submitted an application to the U.S. Food and Drug Administration for oral Wegovy as a potential treatment for metabolic dysfunction-associated steatohepatitis.
The original injectable version of Wegovy is approved for this indication, but the pill offers a more convenient option. It could be successful in this niche and continue driving Novo’s sales higher. Second, Novo will launch new products to strengthen its position in the diabetes and weight-loss markets.
It is inching closer to approval for CagriSema, a medicine that beat Wegovy in a head-to-head Phase 3 clinical trial for weight loss. CagriSema also posted strong clinical trial results in diabetes. This medicine could help Novo steal some market from its biggest competitor, Eli Lilly (LLY -0.79%).
Third, Novo has several pipeline candidates that could improve its approved lineup over time. The company’s Phase 3 pipeline features zenagamtide, a promising diabetes and weight-loss medicine that is being developed in subcutaneous and oral formulations.
The weight loss market is growing rapidly, and this product, along with others, may help Novo ride that tailwind for a long time, even as competition intensifies. Novo may still experience some clinical setbacks, but after the beating it took over the past two years, the company is slowly staging a comeback. In my view, the stock is attractive ing its third-quarter results.
Read Next
Novo Nordisk: 3 Key Takeaways for Long-Term Investors
Novo Nordisk (NVO) Q3 2026 Earnings Call Transcript
3 Dirt Cheap Dividend Stocks to Buy in November 2026
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?
Novo Has Big Plans for 2030. Should You Buy the Stock Now?
•By Brendan Coffey
Amgen vs. Novo Nordisk: Which Healthcare Giant’s Stock Is a Better Buy in 2026?
About the Author
Prosper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks. Before The Motley Fool, Prosper wrote about investing topics ranging from stock market news to private equity for various companies. He holds a master’s degree in corporate finance from the University of Maryland Global Campus.
Stocks Mentioned
Novo Nordisk
NYSE: NVO
$40.31
(+0.03%)+$0.01
Motley Fool Stock Advisor’s Latest Pick
—% Avg Return
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.
Sumber Artikel:
Fool.com